Ipca Laboratories Limited (NSE:IPCALAB)
India · Delayed Price · Currency is INR 1,524.40
-48.00 (-3.05%)
May 29, 2026, 3:29 PM IST
Ipca Laboratories Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 96,463 | 89,396 | 77,050 | 62,443 | 58,298 |
Other Revenue | 1,745 | 16.3 | 8.4 | 37.9 | 7.1 |
| 98,208 | 89,412 | 77,059 | 62,481 | 58,305 | |
Revenue Growth (YoY) | 9.84% | 16.03% | 23.33% | 7.16% | 7.56% |
Cost of Revenue | 28,227 | 30,815 | 28,475 | 25,229 | 22,080 |
Gross Profit | 69,981 | 58,598 | 48,584 | 37,252 | 36,225 |
Selling, General & Admin | 21,602 | 20,055 | 17,314 | 13,076 | 11,964 |
Other Operating Expenses | 26,849 | 21,618 | 18,412 | 14,537 | 11,374 |
Operating Expenses | 52,632 | 45,625 | 39,268 | 30,218 | 25,635 |
Operating Income | 17,349 | 12,973 | 9,316 | 7,034 | 10,591 |
Interest Expense | -759.4 | -843.2 | -1,373 | -450.9 | -72.4 |
Interest & Investment Income | - | 351.2 | 629.3 | 793.5 | 341.7 |
Earnings From Equity Investments | -75.9 | -22.9 | -62.9 | -129.4 | -211.6 |
Currency Exchange Gain (Loss) | - | 330.1 | 329.5 | -315.1 | 307.9 |
Other Non Operating Income (Expenses) | - | 60.6 | 46.9 | 110.1 | 70.4 |
EBT Excluding Unusual Items | 16,514 | 12,849 | 8,886 | 7,042 | 11,027 |
Merger & Restructuring Charges | - | - | -390.4 | - | - |
Gain (Loss) on Sale of Investments | - | 466.2 | 547.1 | 149.7 | 232.9 |
Gain (Loss) on Sale of Assets | - | 27.6 | 6.2 | 160.5 | -0.3 |
Asset Writedown | - | -3.4 | 2.1 | -28.4 | -113.6 |
Other Unusual Items | -864.3 | -2,051 | -687.1 | - | - |
Pretax Income | 15,649 | 11,289 | 8,364 | 7,324 | 11,146 |
Income Tax Expense | 3,812 | 3,436 | 3,135 | 2,534 | 2,248 |
Earnings From Continuing Operations | 11,838 | 7,852 | 5,229 | 4,790 | 8,898 |
Minority Interest in Earnings | -426.6 | -475.6 | 244.3 | -76.7 | -57.1 |
Net Income | 11,411 | 7,377 | 5,474 | 4,713 | 8,841 |
Net Income to Common | 11,411 | 7,377 | 5,474 | 4,713 | 8,841 |
Net Income Growth | 54.69% | 34.77% | 16.13% | -46.69% | -22.45% |
Shares Outstanding (Basic) | 254 | 254 | 254 | 254 | 254 |
Shares Outstanding (Diluted) | 254 | 254 | 254 | 254 | 254 |
Shares Change (YoY) | -0.00% | - | - | - | 0.17% |
EPS (Basic) | 44.98 | 29.08 | 21.57 | 18.58 | 34.85 |
EPS (Diluted) | 44.98 | 29.08 | 21.57 | 18.58 | 34.85 |
EPS Growth | 54.70% | 34.77% | 16.13% | -46.69% | -22.58% |
Free Cash Flow | 4,860 | 5,458 | 5,334 | 3,113 | 3,771 |
Free Cash Flow Per Share | 19.16 | 21.51 | 21.02 | 12.27 | 14.87 |
Dividend Per Share | - | 4.000 | 4.000 | 4.000 | 4.000 |
Gross Margin | 71.26% | 65.54% | 63.05% | 59.62% | 62.13% |
Operating Margin | 17.67% | 14.51% | 12.09% | 11.26% | 18.16% |
Profit Margin | 11.62% | 8.25% | 7.10% | 7.54% | 15.16% |
Free Cash Flow Margin | 4.95% | 6.10% | 6.92% | 4.98% | 6.47% |
EBITDA | 21,530 | 16,668 | 12,644 | 9,460 | 12,749 |
EBITDA Margin | 21.92% | 18.64% | 16.41% | 15.14% | 21.87% |
D&A For EBITDA | 4,181 | 3,695 | 3,328 | 2,427 | 2,158 |
EBIT | 17,349 | 12,973 | 9,316 | 7,034 | 10,591 |
EBIT Margin | 17.67% | 14.51% | 12.09% | 11.26% | 18.16% |
Effective Tax Rate | 24.36% | 30.44% | 37.48% | 34.59% | 20.17% |
Revenue as Reported | 98,208 | 90,324 | 78,298 | 63,699 | 58,964 |